CYP3A4 and cystic fibrosis: Previous studies have shown that posaconazole can inhibit FK506 metabolism by cytochrome P450 (CYP3A4) in cystic fibrosis lung transplant patients to result in ∼3-fold increased levels of FK506 [44], [45].